Metformin may have dual effect in breast cancer

May 9, 2012
Metformin may have dual effect in breast cancer

(HealthDay) -- For women without diabetes and with operable breast cancer, administration of metformin prior to surgery does not significantly affect the proliferative marker Ki-67 overall, but drug effects are observed according to homeostasis model assessment (HOMA), particularly in luminal B tumors, according to a study published online May 7 in the Journal of Clinical Oncology.

Bernardo Bonanni, M.D., of the European Institute of Oncology in Milan, and colleagues conducted a randomized trial involving 200 women without diabetes and with operable early-stage who were given either metformin or placebo. The authors sought to investigate the effect of metformin given before surgery on Ki-67.

The researchers found that metformin did not significantly affect Ki-67 compared with placebo. However, in women with HOMA index of greater than 2.8, Ki-67 decreased nonsignificantly, by 10.5 percent, compared with a nonsignificant increase of 11.1 percent in those with HOMA index of 2.8 or lower. In luminal B tumors, metformin had a different effect according to HOMA index (Pinteraction = 0.05). Drug effect modification was demonstrated, with similar trends seen for , waist/hip girth-ratio, , and C-reactive protein.

"In conclusion, our results suggest a heterogeneous effect of metformin on breast cancer proliferation depending on insulin resistance and other factors reflecting altered energy balance, with a trend to a decreased proliferation in women with elevated HOMA index and an opposite trend in women with normal insulin sensitivity," the authors write.

The metformin and placebo used in the study were donated by Laboratori Guidotti in Pisa, Italy.

Explore further: Metformin appeared to slow prostate cancer growth

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Metformin appeared to slow prostate cancer growth

April 1, 2012
The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

Metformin may lower risk for oral cancer development

April 2, 2012
New findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research, suggest that metformin may protect against oral cancer.

Researchers test a drug-exercise program designed to prevent type 2 diabetes

December 6, 2011
(Medical Xpress) -- Kinesiology researcher Barry Braun of the University of Massachusetts Amherst and colleagues recently reported unexpected results of a study suggesting that exercise and one of the most commonly prescribed ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.